Journalist Jesse Singal took issue with Dr. Rose Lovell and Dr. AJ Eckert's guest posts about Abigail Shrier's book on transgender teens, Dr. Harriet Hall's review of the book, and the medical care of these teens, claiming that the posts contained "19 errors." In this post, Dr. Lovell responds to her share of these "19 errors," most of which are not errors.
A critical, science-based analysis of Abigail Shrier's book Irreversible Damage.
Paid speeches at lavish events touting drugs and medical devices risk charges of anti-kickback law violations, warns a recent government Special Fraud Alert. Will companies and doctors take heed this time?
Libella Gene Therapeutics, LLC made the news last week for announcing a "pay-to-play" trial of its telomerase-based anti-aging gene therapy. What was shocking about the announcement was not that it was a "pay-to-play" trial, given that such trials have become all too common, but rather the price of enrollment: $1 million. Worse, the trial is being conducted in Colombia; the therapy doesn't...
Nurse practitioner aggressively advertises a plethora of aesthetic treatments, some of which are dubious. It's legal, but is it ethical?
A CME article in American Family Physician misrepresents the evidence, claiming acupuncture has been proven safe and effective. An accompanying editorial gives despicable advice on how to manipulate patients to accept this theatrical placebo.
There's no reliable evidence that an infusion of blood plasma from a young donor will benefit an older person, and there are risks, but Ambrosia Health is selling "young blood" infusions for thousands of dollars anyway. The FDA has taken notice.
Last week, Annabelle Potts, a girl with the deadly brain cancer DIPG, passed away. She had made the news in Australia and worldwide because she had been treated at Clínica 0-19 in Monterrey, Mexico, where Drs. Alberto Garcia and Alberto Siller treat DIPG patients with a secret unproven mix of intra-arterial chemotherapy injected directly into the arteries feeding the brainstem, all while...